These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 36397636)

  • 1. Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics.
    Ramasamy T; Ruttala HB; Munusamy S; Chakraborty N; Kim JO
    J Control Release; 2022 Dec; 352():861-878. PubMed ID: 36397636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense technology: an overview and prospectus.
    Crooke ST; Baker BF; Crooke RM; Liang XH
    Nat Rev Drug Discov; 2021 Jun; 20(6):427-453. PubMed ID: 33762737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Antisense Oligonucleotides Are Coming of Age.
    Bennett CF
    Annu Rev Med; 2019 Jan; 70():307-321. PubMed ID: 30691367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absorption, Distribution, Metabolism, and Excretion of US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.
    Migliorati JM; Liu S; Liu A; Gogate A; Nair S; Bahal R; Rasmussen TP; Manautou JE; Zhong XB
    Drug Metab Dispos; 2022 Jun; 50(6):888-897. PubMed ID: 35221287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
    Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
    Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of a Quality-By-Design Approach to Optimise Lipid-Polymer Hybrid Nanoparticles Loaded with a Splice-Correction Antisense Oligonucleotide: Maximising Loading and Intracellular Delivery.
    Thanki K; Papai S; Lokras A; Rose F; Falkenberg E; Franzyk H; Foged C
    Pharm Res; 2019 Jan; 36(3):37. PubMed ID: 30623253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug Metabolism and Pharmacokinetics of Antisense Oligonucleotide Therapeutics: Typical Profiles, Evaluation Approaches, and Points to Consider Compared with Small Molecule Drugs.
    Takakusa H; Iwazaki N; Nishikawa M; Yoshida T; Obika S; Inoue T
    Nucleic Acid Ther; 2023 Apr; 33(2):83-94. PubMed ID: 36735616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse Drug Reactions and Toxicity of the Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.
    Alhamadani F; Zhang K; Parikh R; Wu H; Rasmussen TP; Bahal R; Zhong XB; Manautou JE
    Drug Metab Dispos; 2022 Jun; 50(6):879-887. PubMed ID: 35221289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The future of antisense oligonucleotides in the treatment of respiratory diseases.
    Ulanova M; Schreiber AD; Befus AD
    BioDrugs; 2006; 20(1):1-11. PubMed ID: 16573347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioconjugated Oligonucleotides: Recent Developments and Therapeutic Applications.
    Benizri S; Gissot A; Martin A; Vialet B; Grinstaff MW; Barthélémy P
    Bioconjug Chem; 2019 Feb; 30(2):366-383. PubMed ID: 30608140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recent progress and prospect in oligonucleotide therapeutics].
    Yoshioka K; Kuwahara H; Nishina K; Nagata T; Yokota T
    Nihon Rinsho; 2015 Jun; 73(6):1057-65. PubMed ID: 26065142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense oligonucleotide-based therapeutics for cancer.
    Dean NM; Bennett CF
    Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense oligonucleotide technology: from EST to therapeutics.
    Giles RV
    Curr Opin Mol Ther; 2000 Jun; 2(3):238-52. PubMed ID: 11249617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration.
    Monine M; Norris D; Wang Y; Nestorov I
    J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):639-654. PubMed ID: 33991294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical Evaluation of the Renal Toxicity of Oligonucleotide Therapeutics in Mice.
    Echevarría L; Goyenvalle A
    Methods Mol Biol; 2022; 2434():371-384. PubMed ID: 35213032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A fluorescent splice-switching mouse model enables high-throughput, sensitive quantification of antisense oligonucleotide delivery and activity.
    Byrnes AE; Roudnicky F; Gogineni A; Soung AL; Xiong M; Hayne M; Heaster-Ford T; Shatz-Binder W; Dominguez SL; Imperio J; Gierke S; Roberts J; Guo J; Ghosh S; Yu C; Roose-Girma M; Elstrott J; Easton A; Hoogenraad CC
    Cell Rep Methods; 2024 Jan; 4(1):100673. PubMed ID: 38171361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Status of Antisense Oligonucleotide-Based Therapy in Neuromuscular Disorders.
    Bizot F; Vulin A; Goyenvalle A
    Drugs; 2020 Sep; 80(14):1397-1415. PubMed ID: 32696107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oligonucleotide delivery: a patent review (2010 - 2013).
    Grijalvo S; Aviñó A; Eritja R
    Expert Opin Ther Pat; 2014 Jul; 24(7):801-19. PubMed ID: 24798406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders.
    Silva AC; Lobo DD; Martins IM; Lopes SM; Henriques C; Duarte SP; Dodart JC; Nobre RJ; Pereira de Almeida L
    Brain; 2020 Feb; 143(2):407-429. PubMed ID: 31738395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient in vivo delivery of antisense oligonucleotide to choroid plexus.
    Piao W; Nishina K; Yoshida-Tanaka K; Kuwahara H; Nishina T; Sakata M; Mizusawa H; Yokota T
    J Med Dent Sci; 2013 Mar; 60(1):9-16. PubMed ID: 23917958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.